Gap junction dysfunction in the prefrontal cortex induces depressive-like behaviors in rats

Area of Science:

• Neuroscience
• Cell Biology
• Psychiatry

Background:

• Glial cell anomalies are increasingly implicated in major depressive disorder (MDD).
• Astrocyte gap junction communication is crucial for glial function, but its role in MDD remains unclear.
• Chronic unpredictable stress (CUS) is a validated rodent model for depression.

Purpose of the Study:

• To investigate alterations in astrocyte gap junction function in the rat prefrontal cortex (PFC) following CUS.
• To explore the potential involvement of gap junction dysfunction in the pathophysiology of depression.
• To examine the therapeutic effects of antidepressants and a glucocorticoid receptor antagonist on CUS-induced changes.

Main Methods:

• Induction of CUS in rats to model depression.
• Assessment of behavioral deficits using sucrose preference test (SPT) and novelty suppressed feeding test (NSFT).
• Analysis of gap junction dye diffusion, connexin 43 (Cx43) expression, and ultrastructure in the PFC.
• Pharmacological interventions with fluoxetine, duloxetine, mifepristone, carbenoxolone (CBX), Gap27, and Gap26.

Main Results:

• CUS exposure led to decreased gap junction permeability, reduced Cx43 expression, and abnormal ultrastructure in the PFC, correlating with depressive-like behaviors.
• Antidepressants and mifepristone reversed CUS-induced cellular and behavioral deficits, suggesting a role for glucocorticoid receptor (GR) activation.
• Pharmacological blockade of gap junctions in the PFC using CBX, Gap27, and Gap26 induced anhedonia and anxiety, mimicking depressive symptoms.

Conclusions:

• Astrocyte gap junction dysfunction in the PFC contributes significantly to the pathophysiology of depression.
• The therapeutic mechanisms of antidepressants and mifepristone may involve the amelioration of gap junction dysfunction.
• Glial gap junction function represents a potential therapeutic target for MDD.